Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH.

J Clin Invest. 1999 Jul;104(2):155-62.

PMID:
10411544
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.

Mace TA, Yamane N, Cheng J, Hylander BL, Repasky EA.

Immunol Invest. 2006;35(3-4):279-96. Review.

PMID:
16916755
[PubMed - indexed for MEDLINE]
3.

APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy.

Bucur O, Ray S, Bucur MC, Almasan A.

Front Biosci. 2006 May 1;11:1549-68. Review.

PMID:
16368536
[PubMed - indexed for MEDLINE]
4.

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.

Sayers TJ, Murphy WJ.

Cancer Immunol Immunother. 2006 Jan;55(1):76-84. Epub 2005 Oct 27. Review.

PMID:
15864587
[PubMed - indexed for MEDLINE]
5.

Targeting death receptors in cancer with Apo2L/TRAIL.

Kelley SK, Ashkenazi A.

Curr Opin Pharmacol. 2004 Aug;4(4):333-9. Review.

PMID:
15251125
[PubMed - indexed for MEDLINE]
6.

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.

Almasan A, Ashkenazi A.

Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48. Review.

PMID:
12787570
[PubMed - indexed for MEDLINE]
7.

Modulation of death receptor pathways in oncology.

de Vries EG, Timmer T, Mulder NH, van Geelen CM, van der Graaf WT, Spierings DC, de Hooge MN, Gietema JA, de Jong S.

Drugs Today (Barc). 2003;39 Suppl C:95-109. Review.

PMID:
14988748
[PubMed - indexed for MEDLINE]
8.

Control of apoptosis signaling by Apo2 ligand.

Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A.

Recent Prog Horm Res. 1999;54:225-34. Review.

PMID:
10548878
[PubMed - indexed for MEDLINE]
9.

The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer.

Mitsiades CS, Poulaki V, Mitsiades N.

J Endocrinol. 2003 Aug;178(2):205-16. Review.

PMID:
12904168
[PubMed - indexed for MEDLINE]
Free Article
10.

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL.

Holland PM.

Cancer Lett. 2013 May 28;332(2):156-62. doi: 10.1016/j.canlet.2010.11.001. Epub 2011 Jan 8. Review.

PMID:
21220186
[PubMed - indexed for MEDLINE]
11.

APO2L/TRAIL: new insights in the treatment of autoimmune disorders.

Anel A, Martinez-Lostao L.

Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):184-99. Review.

PMID:
21827400
[PubMed - indexed for MEDLINE]
12.

The anti-cancer activity of tumour necrosis factor.

Malik S, Balkwill F.

Ann Inst Pasteur Immunol. 1988 May-Jun;139(3):285-8. Review. No abstract available.

PMID:
3048310
[PubMed - indexed for MEDLINE]
13.

[The search for tumor-specific cytotoxic agents: relation to apoptosis-inducing activity].

Sakagami H.

Nihon Yakurigaku Zasshi. 2006 May;127(5):322-8. Review. Japanese. No abstract available.

PMID:
16819235
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk